Price
215.18
+15.57%52W Range
Market Cap
₹798.40 Cr
Traded: ₹508.81 Cr (63.73%) 0.0x
Free Float: ₹188.90 Cr (269.35% of FF traded)
Volume · 60D trend
2.43 Cr 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +10.0% | +2.0% | -- | +1.0% | Decelerating |
| ROE | -- | +33.0% | +31.0% | -- | -- | Decelerating |
| Return | -- | -- | -- | -21.0% | -- | -- |
| Profit | -- | +23.0% | +19.0% | -- | +9.0% | Decelerating |
Quarterly Results
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 26 | 25 | 26 | 24 | 26 | 24 | 25 | 25 | 22 | 21 | 21 | 26 | 21 |
| Expenses | 19 | 17 | 17 | 17 | 16 | 18 | 16 | 16 | 17 | 14 | 15 | 15 | 17 | 17 |
| Operating Profit | 9 | 10 | 8 | 9 | 8 | 8 | 8 | 9 | 8 | 8 | 6 | 6 | 9 | 4 |
| OPM % | 31.7% | 36.4% | 31.8% | 33.9% | 32.8% | 29.7% | 34.8% | 35.4% | 32.6% | 35.4% | 29.4% | 27.9% | 32.8% | 18.6% |
| Other Income | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 10 | 11 | 9 | 9 | 8 | 8 | 9 | 9 | 8 | 8 | 6 | 6 | 8 | 4 |
| Tax % | 25.6% | 27.0% | 23.4% | 27.2% | 25.7% | 24.1% | 26.1% | 26.6% | 26.0% | 29.9% | 18.3% | 27.1% | 24.5% | 36.5% |
| Net Profit | 7 | 8 | 7 | 7 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 4 | 6 | 2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 2.0 | 2.2 | 1.8 | 1.8 | 1.7 | 1.7 | 1.8 | 1.7 | 1.7 | 1.6 | 1.3 | 1.2 | 1.7 | 0.7 |
| Sales Growth (YoY) | 16.9% | 0.0% | 5.3% | 2.7% | -3.6% | 17.8% | 15.9% | 18.3% | -2.9% | 3.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 3.4% | -1.0% | 5.1% | -7.0% | 8.8% | -3.4% | -1.3% | 13.6% | 7.1% | -1.5% | -19.0% | 20.9% | -- |
| OP Growth (YoY) | 12.8% | 22.8% | -3.9% | -1.7% | -2.9% | -1.3% | 37.5% | 50.2% | -3.6% | 96.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -5.6% | 18.6% | -7.2% | 8.5% | 2.8% | -7.3% | -5.0% | 7.2% | 4.6% | 29.1% | 3.8% | -31.2% | 113.5% | -- |
| Profit Growth (YoY) | 16.2% | 26.6% | 0.9% | 3.3% | 2.1% | 7.5% | 37.8% | 48.7% | -3.6% | 141.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 27.1% | 1.1% | 3.5% | 1.8% | 7.6% | 37.5% | 48.7% | -3.5% | 139.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 21.4% | -1.1% | 6.5% | -0.6% | -3.4% | 1.1% | 4.8% | 5.1% | 23.4% | 9.4% | -32.0% | 160.6% | -- |
| OP Margin | -- | 36.4% | 31.8% | 33.9% | 32.8% | 29.7% | 34.8% | 35.4% | 32.6% | 35.4% | 29.4% | 27.9% | 32.8% | 18.6% |
| Net Margin | -- | 30.6% | 26.1% | 26.2% | 25.9% | 24.2% | 27.2% | 26.0% | 24.4% | 26.5% | 22.9% | 20.7% | 24.6% | 11.4% |
| Material Cost % | -- | 44.8% | 47.0% | 44.5% | 48.4% | 55.0% | 49.5% | 45.5% | 53.1% | 47.3% | 53.0% | 52.1% | 51.8% | 60.1% |
| Employee Cost % | -- | 6.3% | 8.5% | 7.2% | 7.3% | 4.8% | 4.9% | 4.7% | 4.6% | 5.5% | 6.5% | 8.8% | 7.0% | 8.9% |
| P/S | 7.60 | 6.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 27.91 | 23.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.88 | 5.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Company has received announcement in relation of public offer to the public shareholder of the Company issued by IIFL Capital Services Limited on behalf of Indo Borax & Chemical Limited ....
IIFL Capital Services Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Kronox Lab Sciences Ltd ("Target ....
Joint Press Release titled Indo Boarx to acquire 64.26% stake in Kronox Lab Sciences Limited
Promoters informed the Company about the SPA executed by them with Indo Borax & Chemicals Limited (Acquirer) and Zenrock Chemicals Private Limited (PAC)
Announcement of SPA executed by Promoter with Indo Borax & Chemicals Limited (Acquirer)and Zenrock Chemicals Privated Limited (PAC)
Newspaper Advt. for Unaudited Financial Results for the Quarter ended June 30, 2026
Board Meeting held today to consider and approve Unaudited Standalone Financial Results for the Quarter ended June 30, 2026 and fix date of AGM and Record Date.
Unaudited Financial Results for the quarter ended June 30, 2026
The Register of Members and Share transfer Book of the Company will remain closed from Thursday September 10, 2026 to Wednesday September 16, 2026 (both the days inclusive) for the purpose ....
Record Date for the purpose of Final Dividend (if approved by Shareholders) will be Wednesday, September 09, 2026
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Unaudited Standalone Financial ....
The Exchange has sought clarification from Kronox Lab Sciences Ltd on July 16, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Clarification sort by the exchange under Regulation 30
Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018
Closure of Trading Window for the Quater ending June, 2026
Submission of Annual Secretarial Compliace Report for the Year ended March, 2026
Newapaper publication for Audited Financial Results for the Quarter and Year ended March 31, 2026
Outcome of Board Meeting held today to consider and approve Audited Standalone Financial Results and Dividend
Board Meeting held today to consider and approve Audited Standalone Financial Results for the Quarter and Year ended on March 31, 2026
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Audited Standalone Financial ....
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Clarification on Price Movement
The Exchange has sought clarification from Kronox Lab Sciences Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading window for the Quarter and Year ending March 31, 2026
Newspaper Publication for Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025
Board Meeting held on Saturday, February 14, 2026 to consider and approver unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025
Outcome of Board Meeting held on Saturday, February 14, 2026 to Consider and Approve the Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un- audited Financial Results ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter and Nine Months ended December 31 , 2025
Closure of Trading Window for the Quarter and Nine Months ending December, 2025
Newspaper Announcement for Un-audited Financial Results for the Quarter and Half Year ended September 30, 2025
Outcome of Board Meeting held today to consider Unaudited Financial Results for the Quarter and Half year ended September, 2025.
Board Meeting held today to consider Unaudited Financial Results for the Quarter and Half Year ended September, 2025
Update on Development Status of Unit-IV: GPCB has given Consent To Establish for Unit-IV
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve Unaudited Financial Results ....
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter ended September, 2025
UPDATE ON DEVELOPMENT OF UNIT-IV AT DAHEJ, The Company has received Approval of ENVIRONMENTAL CLEARANCE from Central Government.
Pursuant to Regulation 44 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 we enclose herewith Voting Results for the 16th Annual General Meeting held on 18th August, 2025
Please find attached Combined Scrutinizer Report for the Annual General Meeting held on 18th August, 2025
Proceeding of 16th Annual General meeting held on Monday, August 18, 2025
Meeting of Board of Directors held today to consider and approve to Un-audited Financial Results for the quarter ended June 30, 2025
Outcome of Meeting of Board of Director of the Company held today to consider and approve Un-audited financial Results for the quarter ended June 30, 2025
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 ,inter alia, to consider and approve Un-audited Standalone Financail ....
Newspaper Publication of Notice of the 16th Annual General Meeting of the Company on Monday, August 18, 2025
We wish to inform you that the 16th Annual General Meeting (AGM) of the KRONOX Lab Sciences Limited (Company) is scheduled to be held on Monday, August 18, 2025 at 11.00 AM through Video ....
In terms of the provision of Regulation 30 of SEBI (LODR), 2015, Please find attached enclosed the Notice of 16th Annual General Meeting of the Company to be held on Monday, August 18, 2025
Appointment of M/s. Devesh Pathak & Associates as Secretarial Auditor of the Company subject to Shareholders Approval in ensuing AGM